Idiopathic pulmonary fibrosis: From clinical trials to real-life experiences

European Respiratory Review

Volumn 24, Issue 137, 2015, Pages 420-427

  Harari, Sergio ^a   Caminati, Antonella ^a  

^a IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; NINTEDANIB; PIRFENIDONE; PLACEBO; PYRIDONE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL DISEASE; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MORTALITY; NAUSEA; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONAL EXPERIENCE; PHOTOSENSITIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; WALKING; EVIDENCE BASED MEDICINE; IDIOPATHIC PULMONARY FIBROSIS; METHODOLOGY; PROCEDURES; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84940669065     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0042-2015     Document Type: Review

References (35)

1. American Thoracic Society (ATS), and European Respiratory Society (ERS). Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646–664.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
3. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; 9: CD003134.
4. Richeldi L. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 147–151.
5. King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014; 189: 825–831.
6. Collard HR, Brown KK, Martinez FJ, et al. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest 2014; 146: 1256–1262.
7. Atkins CP, Loke YK, Wilson AM. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials. Respir Med 2014; 108: 376–387.
8. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
9. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
10. European Medicines Agency. CHMP assessment report EMA/CHMP/115147/2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002154/WC500103073.pdf Date last updated: December 16, 2010. Date last accessed: November 19, 2014.
11. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial on pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040–1047.
12. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821–829.
13. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–1769.
14. Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. J Med Chem 2015; 58: 1053–1063.
15. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434–1445.
16. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079–1087.
17. U.S. Food and Drug Administration. FDA approves Esbriet to treat idiopathic pulmonary fibrosis. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm Date last updated: October 15, 2014. Date last accessed: January 20, 2015.
18. Bonella F, Wessendorf TE, Costabel U. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose [Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis]. Dtsch Med Wochenschr 2013; 138: 518–523.
19. Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013; 107: 1431–1437.
20. Arai T, Inoue Y, Sasaki Y, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 2014; 52: 136–143.
21. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199–207.
22. Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108: 224–226.
23. Loeh B, Drakopanagiotakis F, Bandelli GP, et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015; 191: 110–113.
24. Harari S, Caminati A, Albera C, et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir Med 2015; 109: 904–913.
25. Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev 2015; 24: 58–64.
26. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684–691.
27. Koschel D, Cottin V, Skold M, et al. Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment. Eur Respir J 2014; 44: Suppl. 58, 1904.
28. Kreuter M. Pirfenidone: an update on clinical trial data and insights from everyday practice. Eur Respir Rev 2014; 23: 111–117.
29. Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015; 46: 186–196.
30. Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 198–205.
31. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740–747.
32. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968–1977.
33. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014; 31: 375–391.
34. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2: 933–942.
35. Costabel U. The changing treatment landscape in idiopathic pulmonary fibrosis. Eur Respir Rev 2015; 24: 65–68.